Lv1
50 积分 2025-06-06 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
14天前
已完结
Novel drug targets in 2025
20天前
已完结
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
1个月前
已完结
The making of multispecific immunoglobulins – a clinical perspective
1个月前
已完结
The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia
1个月前
已完结
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients
1个月前
已完结
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
2个月前
已完结
140 (PB128): ATV-1601 is a Potent and Selective Allosteric Inhibitor of AKT1-E17K and Shows Profound and Durable Regressions in AKT1-E17K-Driven Patient Derived Xenograft Models
2个月前
已关闭
Emerging landscape of KRAS inhibitors in cancer treatment
2个月前
已完结
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment
2个月前
已完结
皖公网安备34019202002308
